… , DPP-4, α-thrombin and coagulation Factor Xa known inhibitors, with several of them …
promising in silico results may warrant further evaluation for viral anticipation. DPP-4 inhibitors with …

… Here, in silico drug discovery tools were utilized to evaluate … against SARS-CoV-2 main
protease (M pro ). Molecular … protease drugs as prospective SARS-CoV-2 M pro inhibitors. …

… medicinal plants against DENV NS2B/NS3 Protease and to screen innovative flavonoids that
could aid in inhibition of the DENV infection. We also evaluated the drug capability and anti-…

… In order to contribute with further studies related to developing more effective drugs, in this
work was evaluated a broad library of protease inhibitors available in the ZINC database (…

… We employed virtual screening tools to search for new inhibitors to accelerate the drug … -2
main protease and ranked by their binding energy. Furthermore, in-silico ADME studies were …

… of NS2B/NS3 protease inhibitors recent development applying in vitro and in silico method.
… against NS2B/NS3pro were evaluated using a protease inhibition assay. Moreover, plaque, …

… the interactions between the inhibitor molecule and the vital … in silico evaluation of atazanavir
and its new ten designed analogs (protease inhibitors) was performed on the HIV protease (…

… We used a ligand-based in silico approach to screen compounds that structurally resembled
ten known competitive inhibitors of NS2B-NS3pro but contained significant modifications. …

… novel potent inhibitor, we performed blind docking studies on the main virus protease M pro
… and Mizolastine appear as potential inhibitors of this protease. When docked against M pro …

… as HCV NS3/4A protease inhibitors. We engaged in … virtual evaluation which shed more
light on the interaction of molecule 67, D3, and R with the target receptor (HCV NS3/4a protease …